What is the risk of deep‑vein thrombosis (DVT) in an otherwise healthy adult woman undergoing laparoscopic myomectomy?

Risk of DVT in Laparoscopic Myomectomy

The risk of DVT following laparoscopic myomectomy in an otherwise healthy woman is very low, likely less than 0.5%, and routine pharmacological thromboprophylaxis while hospitalized is recommended, but extended prophylaxis beyond discharge is not necessary for this low-risk population.

Understanding the Risk Profile

The evidence base for laparoscopic gynecologic surgery in healthy patients demonstrates consistently low VTE rates:

• A Danish study of 671 women undergoing laparoscopic hysterectomy and vaginal prolapse surgery found 0% incidence of VTE within 3 months postoperatively 1. This was achieved with selective use of thromboprophylaxis in only 32.8% of patients, and notably without graduated compression stockings.

• For laparoscopic procedures in non-obese patients with benign disease, the overall VTE rate was only 0.25% within 30 days when patients were positioned in reverse-Trendelenburg (the typical position for laparoscopic myomectomy) 2.

• Among gynecological surgery patients more broadly, the overall DVT incidence was 9.20%, but this included open procedures and cancer surgeries 3. When isolated to laparoscopic approaches for benign disease in healthy patients, the risk drops substantially.

Guideline-Based Recommendations

Inpatient Prophylaxis (Strong Recommendation)

All patients undergoing laparoscopic myomectomy should receive VTE prophylaxis while hospitalized 4. This includes:

• Mechanical prophylaxis: Compression stockings and/or intermittent pneumatic compression devices
• Pharmacological prophylaxis: Low molecular weight heparin (LMWH) or unfractionated heparin during the hospital stay

Both interventions carry strong recommendations with high-quality evidence 4.

Extended Prophylaxis (Not Recommended for Low-Risk Patients)

Extended thromboprophylaxis beyond hospital discharge is not recommended for healthy women undergoing laparoscopic myomectomy 4. The rationale includes:

• Post-discharge VTE rates are extremely low (0.60-0.73%) in general abdominal/pelvic surgery 4
• The absolute risk reduction with extended prophylaxis is minimal when baseline risk is already very low
• Logistical challenges (cost, daily injections, patient compliance) outweigh benefits in low-risk populations 5

The studies supporting extended prophylaxis (28 days) were conducted primarily in cancer surgery patients undergoing open procedures, where baseline VTE risk is substantially higher 5. These findings should not be extrapolated to healthy women having minimally invasive surgery for benign conditions.

Risk Stratification Factors

While your patient is "otherwise healthy," consider these factors that would elevate risk and potentially warrant extended prophylaxis:

Procedure-related factors 2:

• Operative time >106 minutes (increases risk 3.5-fold)
• Inpatient vs. outpatient procedure (increases risk 2.5-fold)
• Conversion to laparotomy

Patient-related factors 3:

• Age ≥50 years
• Varicose veins
• Hypertension
• Bed rest ≥48 hours postoperatively

If ≥3 risk factors are present, the patient moves to high-risk category and extended prophylaxis should be reconsidered 3.

Common Pitfalls to Avoid

1. Over-treating low-risk patients: The Danish study challenges routine use of compression stockings and universal pharmacological prophylaxis in day surgery settings 1. However, given the strong guideline recommendations and minimal harm, maintaining inpatient prophylaxis remains prudent.

2. Assuming all gynecologic surgery data applies equally: Most studies combine various procedures and patient populations. Laparoscopic myomectomy in healthy women represents the lowest-risk subset.

3. Missing the 7-day window: If DVT occurs, 97% of cases manifest within 7 days postoperatively 3, making early mobilization and compliance with inpatient prophylaxis critical.

Practical Algorithm

For an otherwise healthy woman undergoing laparoscopic myomectomy:

1. Preoperatively: Assess for additional risk factors (age, varicose veins, hypertension, anticipated operative time)

2. Intraoperatively: Utilize intermittent pneumatic compression devices

3. Postoperatively (inpatient):

   • Continue mechanical prophylaxis
   • Administer LMWH until discharge
   • Encourage early mobilization

4. At discharge:

   • If 0-2 risk factors: No extended prophylaxis needed
   • If ≥3 risk factors: Consider 28-day LMWH or rivaroxaban 10 mg daily

5. Patient education: Report leg swelling, pain, or shortness of breath immediately within first 7 days